Data Monitoring Committee Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study Pharmaceutical Investing
3D Signatures Inc. Announces Successful Scoring Model Development and Analytical Validation of the Telo-HL(TM) Test for Hodgkin’s Lymphoma Genetics Investing
Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment Genetics Investing
Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update Pharmaceutical Investing
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial Biotech Investing